ClinicalTrials.gg
Active, not recruitingNCT04067726TRIDENTUpdated Oct 9, 2026Results posted

RANKL Inhibition and Mammographic Breast Density

A Phase 2 interventional study of Denosumab and Placebo in Dense Breasts, sponsored by Washington University School of Medicine. Active, not recruiting at 1 site in United States. Open to female participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Washington University School of Medicine · Phase 2, Interventional, and Prevention

How we know

Updated Oct 9, 2026Results postedStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
40 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 24 studies testing denosumab in Breast Neoplasms — none open to participants now, 3 under way, 2 of them phase 3. Denosumab · Breast Neoplasms.

Enrollment
9th of 24
210 · median 53
Started
2019
the only one that year
Phase 2
9 of 24
none open now
Registered
23rd of 24
by date
Lead sponsor
2 of 24
Washington University School of Medicine

Among the 24 studies testing denosumab in Breast Neoplasms, this one is the 9th largest by enrollment, is the only one that started in 2019, is one of 9 in phase 2, and was the 23rd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

None of the 24 studies testing denosumab in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 40 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 24 studies testing denosumab in Breast Neoplasms as a file.
02

Study summary

Data supporting a role for RANKL signaling in mammographic density and breast cancer development has begun to emerge, but clinical trial data providing definitive evidence that would allow the adoption of RANKL inhibition in primary breast cancer prevention are not yet available. The hypothesis is that RANKL inhibition with denosumab will decrease mammographic density in high-risk premenopausal women with dense breasts. To address this, the investigators have developed this clinical trial to quantify the impact of RANKL inhibition on mammographic density in high-risk premenopausal women with dense breasts and to determine the effect of RANKL inhibition on markers of proliferation and biomarkers of breast cancer risk. Successful demonstration that RANKL inhibition reduces mammographic density could open up additional approaches to primary breast cancer prevention in high-risk premenopausal women, who do not have dominant genetic predisposition.

03

Conditions studied

  • Dense Breasts

Browse trials for

Keywords

  • Mammographic density
  • Breast cancer
  • RANKL
  • Denosumab
  • Prevention
  • Premenopausal
04

Who can participate

The criteria were revised on the registry on Oct 9, 2026. See what changed

Ages eligible
40 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female.
  • Premenopausal (when menopausal status is uncertain, the investigators will measure follicle-stimulating hormone and estradiol to ascertain that a participant is premenopausal)
  • At least 40 years of age.
  • Dense breasts on routine mammogram (BI-RADS Category C and D)
  • Able to understand and willing to sign an IRB-approved written document.

Exclusion criteria

Exclusion Criteria:

  • History of breast or any other invasive cancer except for DCIS (ductal carcinoma in situ) who received only lumpectomy, LCIS (lobular carcinoma in situ), atypical hyperplasia, non-melanoma skin cancer, carcinoma in situ of the cervix.
  • Current use of tamoxifen, aromatase inhibitors, or bisphosphonates, or RANKL inhibitors
  • Concurrent participation in another cancer chemoprevention trial (unless no longer receiving the intervention).
  • Pregnant, lactating, or planning to get pregnant while the trial is ongoing.
  • Recent history of invasive dental procedure (e.g. tooth extraction, dental implant, oral surgery).
  • Unhealed and/or planned dental/oral surgery.
  • History of osteonecrosis/osteomyelitis of the jaw.
  • History of osteoporosis or severe osteopenia.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
210 participants (actual)

Study arms

  • Experimental
    Denosumab

    * Subcutaneous injection of denosumab at a dose of 60 mg at two time points: baseline and 6 months * Participants will also be instructed to take calcium and vitamin D supplements daily for 12 months between baseline examination and 12-month mammographic breast density examination. * Mammographic breast density will be assessed at three time points in all participants: baseline, 12 months, and 24 months. A 36-month optional assessment may also occur. * Biopsies and blood draws will occur for research purposes at baseline and 12 months.

    Drug: Denosumab · Drug: Calcium · Drug: Vitamin D3 · Procedure: Core needle biopsy · Procedure: Blood draw

  • Placebo comparator
    Placebo

    * Subcutaneous injection of the placebo at a dose of 60 mg at two time points: baseline and 6 months * Participants will also be instructed to take calcium and vitamin D supplements daily for 12 months between baseline examination and 12 month mammographic breast density examination * Mammographic breast density will be assessed at three time points in all participants: baseline, 12 months, and 24 months. A 36 month optional assessment may also occur. * Biopsies and blood draws will occur for research purposes at baseline and 12 months.

    Drug: Placebo · Drug: Calcium · Drug: Vitamin D3 · Procedure: Core needle biopsy · Procedure: Blood draw

Interventions

  • Denosumab is commercially available and will be provided at no cost to participants.

    Also known as: Prolia

  • DrugPlacebo

    Placebo will be made available as 1 mL sterile, non-pyrogenic water solution in a single-use prefilled syringe.

  • -Participants will be instructed to take calcium (at least 500 mg) daily for 12 months between baseline examination and 12- month mammographic breast density examination.

  • DrugCholecalciferolStudies of CholecalciferolCholecalciferol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will be instructed to take vitamin D3 (at least 400 IU) supplements daily for 12 months between baseline examination and 12- month mammographic breast density examination.

  • ProcedureCore needle biopsy

    Baseline and 12 months

  • ProcedureBlood draw

    Baseline and 12 months

06

What researchers measure

Primary outcomes

  1. Percent Change of Volumetric Percent Density Compared Between Baseline and 12 Months

    -The investigators used volumetric percent density (VPD) as the primary mammographic breast density measure. The VPD percent change at 12 months from baseline was calculated as volumetric percent density at 12 months divided by baseline volumetric percent density minus 1\*100 (i.e., unit of percentage).

    Time frame: At baseline and at 12 months

Secondary outcomes

  1. Percent Change of Volumetric Percent Density Compared Between Baseline and 24 Months

    The VPD percent change at 12 months from baseline was calculated as volumetric percent density at 24 months divided by baseline volumetric percent density minus 1\*100 (i.e., unit of percentage).

    Time frame: At baseline and 24 months

  2. Percent Change of Volumetric Percent Density Compared Between Baseline and 36 Months

    The VPD percent change at 12 months from baseline was calculated as volumetric percent density at 36 months divided by baseline volumetric percent density minus 1\*100 (i.e., unit of percentage).

    Time frame: At baseline and 36 months

Other outcomes

  1. Changes in Expression of Genes Related to Progesterone in Breast Tissue Between the Two Arms

    Time frame: Baseline and 12 months

  2. Changes in Expression of Genes Related to Metabolic Markers in Breast Tissue Between the Two Arms

    Time frame: Baseline and 12 months

  3. Changes in Expression of Immune Related Genes in Breast Tissue Between the Two Arms

    Time frame: Baseline and 12 months

  4. Change in Breast Metabolome Between the Two Arms

    Time frame: Baseline and 12 months

  5. Changes in Expression of Markers of Breast Epithelial and Stromal Proliferation Between the Two Arms

    Time frame: Baseline and 12 months

  6. Changes in Expression of Inflammatory Genes in Breast Tissue Between the Two Arms

    Time frame: Baseline and 12 months

  7. Changes in Expression of Genes Related to RANK in Breast Tissue Between the Two Arms

    Time frame: Baseline and 12 months

07

Results

Posted Oct 9, 2026

Participant flow

Participant flow — Overall Study
MilestoneDenosumabPlacebo
Started105105
Completed101102
Not completed43
Withdrew: Lost to follow-up42
Withdrew: Participant withdrawal or refusal after beginning protocol therapy01

Outcome measures

PrimaryPercent Change of Volumetric Percent Density Compared Between Baseline and 12 Months

-The investigators used volumetric percent density (VPD) as the primary mammographic breast density measure. The VPD percent change at 12 months from baseline was calculated as volumetric percent density at 12 months divided by baseline volumetric percent density minus 1\*100 (i.e., unit of percentage).

Time frame:
At baseline and at 12 months
Reported as:
Mean · VPD percent change
Percent Change of Volumetric Percent Density Compared Between Baseline and 12 Months
VPD percent changeDenosumabPlacebo
Percent Change of Volumetric Percent Density Compared Between Baseline and 12 Months-1.13 ± 25.601.59 ± 25.95
SecondaryPercent Change of Volumetric Percent Density Compared Between Baseline and 24 Months

The VPD percent change at 12 months from baseline was calculated as volumetric percent density at 24 months divided by baseline volumetric percent density minus 1\*100 (i.e., unit of percentage).

Time frame:
At baseline and 24 months

Results for this outcome have not been posted.

SecondaryPercent Change of Volumetric Percent Density Compared Between Baseline and 36 Months

The VPD percent change at 12 months from baseline was calculated as volumetric percent density at 36 months divided by baseline volumetric percent density minus 1\*100 (i.e., unit of percentage).

Time frame:
At baseline and 36 months

Results for this outcome have not been posted.

Other pre-specifiedChanges in Expression of Genes Related to Progesterone in Breast Tissue Between the Two Arms
Time frame:
Baseline and 12 months

Results for this outcome have not been posted.

Other pre-specifiedChanges in Expression of Genes Related to Metabolic Markers in Breast Tissue Between the Two Arms
Time frame:
Baseline and 12 months

Results for this outcome have not been posted.

Other pre-specifiedChanges in Expression of Immune Related Genes in Breast Tissue Between the Two Arms
Time frame:
Baseline and 12 months

Results for this outcome have not been posted.

Other pre-specifiedChange in Breast Metabolome Between the Two Arms
Time frame:
Baseline and 12 months

Results for this outcome have not been posted.

Other pre-specifiedChanges in Expression of Markers of Breast Epithelial and Stromal Proliferation Between the Two Arms
Time frame:
Baseline and 12 months

Results for this outcome have not been posted.

Other pre-specifiedChanges in Expression of Inflammatory Genes in Breast Tissue Between the Two Arms
Time frame:
Baseline and 12 months

Results for this outcome have not been posted.

Other pre-specifiedChanges in Expression of Genes Related to RANK in Breast Tissue Between the Two Arms
Time frame:
Baseline and 12 months

Results for this outcome have not been posted.

Adverse events

Collected over Adverse events were tracked for up to 24 months after baseline intervention.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Denosumab0/105 (0%)0/105 (0%)67/105 (63.8%)
Placebo0/105 (0%)0/105 (0%)64/105 (61%)
Most frequent other events
Showing 10 of 66
Most frequent other events
EventDenosumabPlacebo
BruisingInjury, poisoning and procedural complications24/10526/105
Muscle CrampMusculoskeletal and connective tissue disorders10/1058/105
MyalgiaMusculoskeletal and connective tissue disorders8/1054/105
ArthralgiaMusculoskeletal and connective tissue disorders7/1054/105
ParesthesiaNervous system disorders6/1053/105
ToothacheGastrointestinal disorders1/1055/105
Periodontal DiseaseGastrointestinal disorders3/1054/105
PruritusSkin and subcutaneous tissue disorders4/1053/105
NauseaGastrointestinal disorders2/1053/105
FatigueGeneral disorders3/1052/105

Baseline characteristics

Age, Continuous
Age, Continuous(years)DenosumabPlaceboTotal
Mean46 (40 to 55)46 (40 to 55)46 (40 to 55)
Sex: Female, Male
Sex: Female, Male(Participants)DenosumabPlaceboTotal
Female105105210
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DenosumabPlaceboTotal
Hispanic or Latino044
Not Hispanic or Latino104100204
Unknown or Not Reported112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DenosumabPlaceboTotal
American Indian or Alaska Native000
Asian303
Native Hawaiian or Other Pacific Islander000
Black or African American151429
White8490174
More than one race202
Unknown or Not Reported112
Region of Enrollment
Region of Enrollment(participants)DenosumabPlaceboTotal
United States105105210
08

Study locations

1 site
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified participant data used in generating tables and figures in published manuscripts.

Time frame: IPD will be shared beginning 12 months, and ending 24 months following article publication.

Access criteria: IPD will be shared with investigators who propose a methodologically sound proposal. These proposals should have been reviewed and approved by independent review committees, including institutional review boards. Proposals should be directed to the Principal Investigator, who will review the request with other co-Investigators. Proposals may also be subject to further review by the Protocol Review Monitoring Committee and Institutional Review Board at Principal Investigator's institution. Requestors will need to sign an institutional data access agreement to gain access to the data.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Sep 2025, 72 months.

Results were first posted in Oct 2026, 1 year after primary completion.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's 72 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

Completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2027, on Oct 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2019
First posted
Aug 26, 2019
StartActual
Aug 27, 2019
Primary completionActual
Sep 17, 2025
CompletionEst.
Sep 30, 2027was Aug 2026
Results first posted
Oct 9, 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 9, 2026
Study completion
Aug 31, 2026→Sep 30, 2027
Oct 9, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedPremenopausal (when menopausal status is uncertain, the investigators will measure follicle-stimulating hormone and estradiol to ascertain that a partcipantparticipant is premenopausal)
Oct 9, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Change in mammographic breast density between the two arms as measured by volumetric percent densityNow Percent Change of Volumetric Percent Density Compared Between Baseline and 12 MonthsTime frame: From baseline to 12 months → At baseline and at 12 months
Oct 9, 2026
Secondary outcomes
9 added, 9 removed
What changed in the outcomes
  • AddedPercent Change of Volumetric Percent Density Compared Between Baseline and 24 MonthsTime frame: At baseline and 24 months
  • AddedPercent Change of Volumetric Percent Density Compared Between Baseline and 36 MonthsTime frame: At baseline and 36 months
  • RemovedChange in mammographic breast density between the two arms as measured by volumetric percent densityTime frame: From baseline to 24 months
  • RemovedChange in mammographic breast density between the two arms as measured by volumetric percent densityTime frame: From 12 months to 24 months
  • RemovedChange in expression gene related to RANK in breast tissue compared between the two armsTime frame: Baseline and 12 months
  • RemovedChange in expression gene related to progesterone in breast tissue compared between the two armsTime frame: Baseline and 12 months
  • RemovedChange in expression gene related to metabolics in breast tissue compared between the two armsTime frame: Baseline and 12 months
  • RemovedChange in expression gene related to immune in breast tissue compared between the two armsTime frame: Baseline and 12 months
  • RemovedChange in expression gene related to inflammatory in breast tissue compared between the two armsTime frame: Baseline and 12 months
  • RemovedChange in expression of markers of breast epithelial and stromal proliferation compared between the two armsTime frame: Baseline and 12 months
  • RemovedChange in breast metabolome compared between the two armsTime frame: Baseline and 12 months
  • Addedother outcomeChanges in Expression of Genes Related to Progesterone in Breast Tissue Between the Two ArmsTime frame: Baseline and 12 months
  • Addedother outcomeChanges in Expression of Genes Related to Metabolic Markers in Breast Tissue Between the Two ArmsTime frame: Baseline and 12 months
  • Addedother outcomeChanges in Expression of Immune Related Genes in Breast Tissue Between the Two ArmsTime frame: Baseline and 12 months
  • Addedother outcomeChange in Breast Metabolome Between the Two ArmsTime frame: Baseline and 12 months
  • Addedother outcomeChanges in Expression of Markers of Breast Epithelial and Stromal Proliferation Between the Two ArmsTime frame: Baseline and 12 months
  • Addedother outcomeChanges in Expression of Inflammatory Genes in Breast Tissue Between the Two ArmsTime frame: Baseline and 12 months
  • Addedother outcomeChanges in Expression of Genes Related to RANK in Breast Tissue Between the Two ArmsTime frame: Baseline and 12 months
Oct 9, 2026
Sponsor
Collaborators added: National Cancer Institute (NCI); collaborators removed: National Institutes of Health (NIH)
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Results posted
    Study completion Aug 31, 2026→Sep 30, 2027
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedPremenopausal (when menopausal status is uncertain, the investigators will measure follicle-stimulating hormone and estradiol to ascertain that a partcipantparticipant is premenopausal)
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Change in mammographic breast density between the two arms as measured by volumetric percent densityNow Percent Change of Volumetric Percent Density Compared Between Baseline and 12 MonthsTime frame: From baseline to 12 months → At baseline and at 12 months
    Secondary outcomes 9 added, 9 removed
    What changed in the outcomes
    • AddedPercent Change of Volumetric Percent Density Compared Between Baseline and 24 MonthsTime frame: At baseline and 24 months
    • AddedPercent Change of Volumetric Percent Density Compared Between Baseline and 36 MonthsTime frame: At baseline and 36 months
    • RemovedChange in mammographic breast density between the two arms as measured by volumetric percent densityTime frame: From baseline to 24 months
    • RemovedChange in mammographic breast density between the two arms as measured by volumetric percent densityTime frame: From 12 months to 24 months
    • RemovedChange in expression gene related to RANK in breast tissue compared between the two armsTime frame: Baseline and 12 months
    • RemovedChange in expression gene related to progesterone in breast tissue compared between the two armsTime frame: Baseline and 12 months
    • RemovedChange in expression gene related to metabolics in breast tissue compared between the two armsTime frame: Baseline and 12 months
    • RemovedChange in expression gene related to immune in breast tissue compared between the two armsTime frame: Baseline and 12 months
    • RemovedChange in expression gene related to inflammatory in breast tissue compared between the two armsTime frame: Baseline and 12 months
    • RemovedChange in expression of markers of breast epithelial and stromal proliferation compared between the two armsTime frame: Baseline and 12 months
    • RemovedChange in breast metabolome compared between the two armsTime frame: Baseline and 12 months
    • Addedother outcomeChanges in Expression of Genes Related to Progesterone in Breast Tissue Between the Two ArmsTime frame: Baseline and 12 months
    • Addedother outcomeChanges in Expression of Genes Related to Metabolic Markers in Breast Tissue Between the Two ArmsTime frame: Baseline and 12 months
    • Addedother outcomeChanges in Expression of Immune Related Genes in Breast Tissue Between the Two ArmsTime frame: Baseline and 12 months
    • Addedother outcomeChange in Breast Metabolome Between the Two ArmsTime frame: Baseline and 12 months
    • Addedother outcomeChanges in Expression of Markers of Breast Epithelial and Stromal Proliferation Between the Two ArmsTime frame: Baseline and 12 months
    • Addedother outcomeChanges in Expression of Inflammatory Genes in Breast Tissue Between the Two ArmsTime frame: Baseline and 12 months
    • Addedother outcomeChanges in Expression of Genes Related to RANK in Breast Tissue Between the Two ArmsTime frame: Baseline and 12 months
    Sponsor Collaborators added: National Cancer Institute (NCI); collaborators removed: National Institutes of Health (NIH)
    + 3 other changes: identifiers, verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04067726
Responsible party
Sponsor
First posted
Aug 26, 2019
Start date
Aug 27, 2019
Primary completion
Sep 17, 2025
Completion
Sep 30, 2027 (estimated)
Results posted
Oct 9, 2026
Last update
Oct 9, 2026

Study contacts

Adetunji T Toriola, M.D., Ph.D.
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion